5.6 Voxilaprevir
Part B - Final decisions on matters not referred to an expert advisory committee
5. New Chemical Entities - medicines for human therapeutic use
5.6 Voxilaprevir
Delegate's final decision
Final decision:
The delegate has made a final decision to create a new Schedule 4 entry for voxilaprevir in the Poisons Standard as follows:
Schedule 4 - New Entry
VOXILAPREVIR.
Implementation date: 1 June 2018
Reasons:
The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the delegate include:
- the risks and benefits of the use of a substance
- Voxilaprevir is a new chemical entity with no clinical/marketing experience in Australia.
- the purposes for which a substance is to be used and the extent of use of a substance
- Voxilaprevir in combination with sofosbuvir and velpatasvir (VOSEVI sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination tablet) is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults.
- the toxicity of a substance
- Reported adverse events from clinical trials include headache, fatigue, diarrhoea and nausea.
- the dosage, formulation, labelling, packaging and presentation of a substance
- The fixed dose combination tablets voxilaprevir in combination with sofosbuvir and velpatasvir (VOSEVI) should be prescribed by medical professionals who are familiar with the management of viral hepatitis. The patients need to be instructed to follow the dosing regimens.
- the potential for abuse of a substance
- Nil.
- any other matters that the Secretary considers necessary to protect public health
- Nil.
Scheduling proposal
The delegate considered an application from the Therapeutic Goods Administration (TGA) for the scheduling of voxilaprevir, a new chemical entity (NCE) for a human therapeutic medicine.
Substance summary
Voxilaprevir is a pan-genotypic inhibitor of the HCV NS3/4A protease. Voxilaprevir acts as a noncovalent, reversible inhibitor of the NS3/4A protease.
VOSEVI (sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination) is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults.
| Property | Voxilaprevir |
|---|---|
| CAS Number | 1535212-07-7 |
| Chemical structure |  |
| Molecular formula | C40H52F4N6O9S |
| Molecular weight | 868.9 g/mol |
| Chemical names | (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-{(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropanesulfonyl) carbamoyl] cyclopropyl}-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21, 22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6] dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide |
| ANN/INN |
eBS ID: 111031 ANN and INN: Voxilaprevir |
Scheduling status
Voxilaprevir is not specifically scheduled in the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - the Poisons Standard that was in effect at the time the decision was made (Poisons Standard March 2018 (SUSMP No. 20)).
International regulations
Voxilaprevir is unclassified in New Zealand, Canada and USA.
Delegate's considerations
The delegate decided to make a delegate-only decision. The Advisory Committee on Medicines Scheduling was not consulted.
The delegate considered the following in regards to this application for scheduling:
- Subsection 52E(1) of the Therapeutic Goods Act 1989;
- The Scheduling Policy Framework (2015) scheduling factors;
- The TGA evaluation report;
- The advice of the Advisory Committee on Prescription Medicines; and
- The new drug application.
The delegate noted that currently there are no issues of concern that require additional control other than by inclusion in Schedule 4.